News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.


Posted on: 08/12/2010

Curr Oncol. 2010 Aug;17(4):124-6.

 

Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.

Oh J, Kutas GJ, Davey P, Morrison M, Perry JR.

Division of Neurology, Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON.

Abstract

Temozolomide (tmz) is an oral alkylating agent used during concurrent and adjuvant chemotherapy for newly diagnosed glioblastoma multiforme. Temozolomide is generally well tolerated and improves survival; however, severe adverse events have occasionally been reported. Here, we report the case of a patient who developed aplastic anemia with related complications in the setting of concurrent tmz treatment with radiotherapy. This case illustrates that aplastic anemia is a rare side effect of tmz that can occur relatively early in the course of concurrent chemotherapy, and underscores the importance of clinician awareness of this potentially devastating side effect.

PMID: 20697524 [PubMed - in process]

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740